Evidence Synthesis
Orchid Pharma Sees Gross Margin Accelerate to 52.99% in Q3, Up from 25.29% in Q2, as Marginal Operating Leverage Improves to -12.26%.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 16 Sept 2026, 02:47
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
Orchid Pharma Sees Gross Margin Accelerate to 52.99% in Q3, Up from 25.29% in Q2, as Marginal Operating Leverage Improves to -12.26%.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 52.99 % | -12.26 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -12.26 % | -29.57 | ▲ |
| REVENUE_GROWTH_YOY | -1.5 % | — | - |
| EPS_ACTUAL | -1.13 INR | -1.085 | ▼ |
| EPS_SURPRISE_PERCENT | -1.39 % | -2.615 | ▲ |
| PRICE_CHANGE_PERCENT | -1.48 % | — | - |
| DAILY_VOLUME | 1,35,720 shares | 1,72,868 | ▼ |
| CLOSE_PRICE | 988.2 INR | 1,003.05 | ▼ |
| NEWS_SENTIMENT_SCORE | 0.67 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 0 count | 2 | ▼ |
| TARGET_PRICE_PREMIUM | -1.98 % | — | - |